一种先进的气动压迫治疗系统可改善腿部体积、液体、脂肪组织厚度、症状和生活质量，并降低脂肪性水肿女性患淋巴水肿的风险。

An Advanced Pneumatic Compression Therapy System Improves Leg Volume and Fluid, Adipose Tissue Thickness, Symptoms, and Quality of Life and Reduces Risk of Lymphedema in Women with Lipedema.

作者信息

Herbst Karen L, Zelaya Carlos, Sommerville Marianne, Zimmerman Tatiana, McHutchison Lindy

机构信息

The Roxbury Institute, Tucson, AZ 85715, USA.

Carolina Vein Center, Durham, NC 27713, USA.

出版信息

Life (Basel). 2025 Apr 30;15(5):725. doi: 10.3390/life15050725.

Lipedema is a painful disease of subcutaneous adipose tissue (SAT) in women. This study determined whether an advanced pneumatic compression device (APCD) improved lipedema SAT depth, swelling, and pain. Women with lipedema started 20-30 mm Hg compression leggings then were randomized to an APCD (Lympha Press Optimal Plus) group for 30 days (treatment; n = 22) or a no APCD (Control; n = 24) group. APCD treatment significantly reduced left leg volume (3D imaging, LymphaTech; < 0.043) and fluid in the left ( = 0.0018) and right legs ( = 0.0476; SOZO, bioimpedance spectroscopy); controls showed no change. Treatment significantly decreased extracellular fluid (ECF) and intracellular fluid (ICF) in left ( = 0.0077; = 0.0060) and right legs ( = 0.0476; ≤ 0.025), respectively. Only ECF decreased significantly in the left ( < 0.0183) and right legs ( = 0.0009) in controls. SAT depth decreased significantly by ultrasound after treatment at the anterior ( ≤ 0.0234) and medial thigh ( ≤ 0.0052), medial knee ( ≤ 0.0002) and posterior calf ( ≤ 0.0118) but not in controls. All signs and symptoms of lipedema improved in the treatment group including swelling ( = 0.0005) and tenderness (pain) of right ( = 0.0003) and left legs ( < 0.0001); only swelling improved in controls ( = 0.0377). In total, 87.5% of RAND SF-36 quality of life improved after treatment ( ≤ 0.0351) compared to 37.5% in controls ( ≤ 0.0475). APCDs are effective treatment for lipedema.

脂肪性水肿是一种发生于女性皮下脂肪组织（SAT）的疼痛性疾病。本研究旨在确定一种先进的气动压缩装置（APCD）是否能改善脂肪性水肿的SAT深度、肿胀及疼痛情况。患有脂肪性水肿的女性开始穿着压力为20 - 30毫米汞柱的紧身裤，然后被随机分为APCD组（Lympha Press Optimal Plus，n = 22）接受治疗30天，或无APCD组（对照组，n = 24）。APCD治疗显著降低了左腿体积（3D成像，LymphaTech；P < 0.043）以及左腿（P = 0.0018）和右腿（P = 0.0476；SOZO生物电阻抗光谱法）中的液体量；对照组无变化。治疗分别显著降低了左腿（P = 0.0077；P = 0.0060）和右腿（P = 0.0476；P ≤ 0.025）的细胞外液（ECF）和细胞内液（ICF）。对照组中仅左腿（P < 0.0183）和右腿（P = 0.0009）的ECF显著降低。治疗后，通过超声检查发现，大腿前部（P ≤ 0.0234）、大腿内侧（P ≤ 0.0052）、膝关节内侧（P ≤ 0.0002）和小腿后部（P ≤ 0.0118）的SAT深度显著降低，而对照组未降低。治疗组中脂肪性水肿的所有体征和症状均有所改善，包括肿胀（P = 0.0005）以及右腿（P = 0.0003）和左腿（P < 0.0001）的压痛（疼痛）；对照组仅肿胀有所改善（P = 0.0377）。总体而言，治疗后RAND SF - 36生活质量改善的比例为87.5%（P ≤ 0.0351），而对照组为37.5%（P ≤ 0.0475）。APCD是治疗脂肪性水肿的有效方法。